News
BCYC
23.26
-2.15%
-0.51
Bicycle Therapeutics Announces Publication Of Article Highlighting Preclinical Data From BT8009 Program In Molecular Cancer Therapeutics
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an
Benzinga · 09/19 20:13
BRIEF-Bicycle Therapeutics Announces Publication Of Article Highlighting Preclinical Data From BT8009 Program
BRIEF-Bicycle Therapeutics Announces Publication Of Article Highlighting Preclinical Data From BT8009 Program
Reuters · 09/19 20:08
Bicycle Therapeutics Discloses Publication of BT8009 Data in Molecular Cancer Therapeutics
Bicycle Therapeutics Discloses Publication of BT8009 Data in Molecular Cancer Therapeutics
MT Newswires · 09/19 16:46
6 Analysts Have This to Say About Bicycle Therapeutics
Analysts have provided the following ratings for Bicycle Therapeutics (NASDAQ:BCYC) within the last quarter:
Benzinga · 09/12 13:52
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $45
Morgan Stanley analyst Jeffrey Hung maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Equal-Weight and lowers the price target from $60 to $45.
Benzinga · 09/12 12:22
Morgan Stanley Lowers Price Target on Bicycle Therapeutics to $45 From $60, Keeps Equalweight Rating
Morgan Stanley Lowers Price Target on Bicycle Therapeutics to $45 From $60, Keeps Equalweight Rating
MT Newswires · 09/12 09:50
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
Benzinga · 09/07 21:45
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results In Patients With Advanced Solid Tumors
Anti-tumor activity observed in heavily pre-treated patients with EphA2-positive ovarian and urothelial cancers; overall response rates of 22% (including one complete response) and 67%,
Benzinga · 09/07 11:17
Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Cowen launched its coverage on oncology-focused biotech Bicycle Therapeutics (NASDAQ:<a href="https://seekingalpha.com/symbol/BCYC?utm_medium=referral&utm_source=webull.com" title="Bicycle Therapeutics plc...
Seekingalpha · 08/31 15:51
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2022
Upgrades
Benzinga · 08/31 14:11
Bicycle Therapeutics Shares Rise After Cowen Initiates Coverage
Bicycle Therapeutics Shares Rise After Cowen Initiates Coverage
MT Newswires · 08/31 12:40
Cowen & Co. Initiates Coverage On Bicycle Therapeutics with Outperform Rating
Cowen &amp; Co. analyst Tara Bancroft initiates coverage on Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform rating.
Benzinga · 08/31 10:23
Billionaire Ken Griffin Goes in on These 3 ‘Strong Buy’ Stocks
As fears of high inflation and the threat of recession become the talk of the town, investors are turning to Wall Street titans for guidance, namely Ken Griffin. Founding hedge fund Citadel in 1990, the firm now boasts over $50 billion worth of assets unde...
TipRanks · 08/24 23:48
Looking Into Bicycle Therapeutics's Return On Capital Employed
According to data from Benzinga Pro, during Q2, Bicycle Therapeutics&#39;s (NASDAQ:BCYC) reported sales totaled $4.38 million. Despite a 2.67% increase in earnings, the company posted a loss of $26.83 million.
Benzinga · 08/22 13:57
Expert Ratings for Bicycle Therapeutics
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Benzinga · 08/22 12:58
SVB Leerink Maintains Outperform on Bicycle Therapeutics, Raises Price Target to $50
SVB Leerink analyst Jonathan Chang maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform and raises the price target from $48 to $50.
Benzinga · 08/22 10:47
--HC Wainwright Lowers Bicycle Therapeutics Price Target to $57 From $65, Maintains Buy Rating
--HC Wainwright Lowers Bicycle Therapeutics Price Target to $57 From $65, Maintains Buy Rating
MT Newswires · 08/05 09:49
Bicycle Therapeutics: Q2 Earnings Insights
  Bicycle Therapeutics (NASDAQ:BCYC) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 08/04 14:01
Bicycle Therapeutics GAAP EPS of -$0.90 misses by $0.04, revenue of $4.38M beats by $0.69M
Bicycle Therapeutics press release (<span class=...
Seekingalpha · 08/04 13:05
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
CAMBRIDGE, England & BOSTON, August 04, 2022--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financi...
Business Wire · 08/04 10:59
More
Webull provides a variety of real-time BCYC stock news. You can receive the latest news about Bicycle Therapeutics Limited through multiple platforms. This information may help you make smarter investment decisions.
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist. The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.